Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.
Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA
The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from legally selling cheap knockoff versions.
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.
Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
Novo Nordisk CEO on US Tariffs, Weight-Loss Sales, Supply Chain
Novo Nordisk A/S Chief Executive Officer and President Lars Fruergaard Jorgensen discusses the potential impact of tariffs coming from Donald Trump's administration in the US, demand for weight-loss medication,
Novo Nordisk Expects Slowing Sales Growth This Year
The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs.
Obesity drug sales help Novo Nordisk beat expectations
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations. The company on Wednesday reported that net sales increased by 26 per cent year on year in 2024 to DKr290bn ($40bn),
Prescriptions for weight loss drugs are skyrocketing, especially among young women. Experts think they know why.
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
Healthy Returns: Why people quit weight loss, diabetes drugs within one year
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Rolling Out3d
The dark side of weight loss drugs no one warns about
New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...
Here's why researchers think most people stop taking weight loss drugs within a year
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...
How Weight-Loss Drugs Can Upend a Marriage
When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...
Pharmacies require stricter weight-loss jab checks
Online pharmacies will now have to employ stricter checks to stop people who are already a healthy weight or have a history ...
Arizona Daily Star6d
Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
To Protect Against Alzheimer’s, Researchers Look to Weight Loss Drugs
One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the ...
RFK Jr, Dr Oz and weight-loss drugs: A high-price health clash may be looming
Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's ...
Half of Americans Support Weight-Loss Drugs Like Ozempic for Obesity, Poll
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...